Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

AstraZeneca Zoladex Marketing Practices Under Investigation By DoJ

  • News

Executive Summary

A Department of Justice investigation into AstraZeneca's Zoladex marketing practices is continuing following the recent settlement with TAP over Lupron.

You may also be interested in...



AstraZeneca Nexium Marketing Draws FTC Scrutiny; DoJ Looking At Prilosec 

The Federal Trade Commission is investigating AstraZeneca's marketing of the omeprazole follow-on product Nexium

AstraZeneca Nexium Marketing Draws FTC Scrutiny; DoJ Looking At Prilosec 

The Federal Trade Commission is investigating AstraZeneca's marketing of the omeprazole follow-on product Nexium

AstraZeneca Self-Markets Nolvadex Generic; Zoladex Settlement Near

AstraZeneca is marketing its own generic version of Nolvadex (tamoxifen) to protect the company from claims that it is exploiting cancer patients in the final months of exclusivity for the drug

Table

View full table

Related Content

Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet
Tags:
Latest Headlines

‘Unbalanced’ EU HTA Timelines Exacerbated By Rare Disease & Cancer Drugs

National Drug Stockpiles Create ‘False Sense Of Security’

Patent Office Issues Proposed Rule For Rarely Successful Director Review Requests

Medicare Spending Forecast For Leqembi Reflects CMS Angst About Alzheimer’s Drug Costs

See All
UsernamePublicRestriction

Register

PS038690

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By